X4 Pharmaceuticals, Inc
corporate_fare Company Profile
X4 Pharmaceuticals, Inc (NASDAQ:XFOR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for XFOR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 6 rated 8 or above. Recent SEC coverage for XFOR spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- X4 Pharmaceuticals Narrows Q3 Loss to 16c/Share, Cash at $187.7M
- X4 Posts Narrower Q3 Loss, $187.7M Cash, and Details K2 Loan Covenants
- X4 Investor Day: 4WARD Enrollment Due Q4 2026, Topline Q1 2028, ~15K-Patient PCN Base Case
- X4 Pharmaceuticals Secures Up to $150M Debt Facility, Repays Prior Loan
- X4 Posts Corporate Presentation With Detailed Phase 2 Data Supporting 4WARD Pivotal Trial
Financial Snapshot
Short Interest & Short Volume
10.86 days to coverFINRA reported short interest of 7,973,579 shares in XFOR as of the October 30, 2026 settlement, a 6.5% increase from the prior period — about 10.9 days to cover at its recent average daily volume. On November 20, 2026, 38.6% of XFOR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.